PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29858976-1	2018	INTRODUCTION: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice.	dpp4i	32-37	dipeptidyl peptidase 4	Homo sapiens	14-19	
24004910-2	2013	FINDINGS: We investigated sera of patients with type 2 diabetes mellitus (T2DM) treated with metformin and sulfonylurea, insulin glargine or a DPP-4 inhibitor (DPP4i).	dpp4i	160-165	dipeptidyl peptidase 4	Homo sapiens	143-148